Last updated: January 29, 2026
Summary Overview
Galderma Laboratories LP v. Teva Pharmaceuticals USA, Inc. is a patent infringement litigation filed in the United States District Court for the District of Delaware. The case revolves around the alleged infringement of U.S. Patent No. 9,573,732 (the '732 patent), which covers a pharmaceutical composition used in dermatology. The dispute primarily questions Teva’s proposed generic version’s compliance with patent rights held by Galderma.
Key details:
- Case Number: 1:17-cv-01783
- Filing Date: August 10, 2017
- Jurisdiction: District of Delaware
- Parties:
- Plaintiff: Galderma Laboratories LP
- Defendant: Teva Pharmaceuticals USA, Inc.
This litigation exemplifies common patent enforcement themes in the pharmaceutical industry, particularly regarding patent validity, inventorship, infringement, and patent expiration.
What is the Nature of the Patent Dispute?
Core issue:
The central legal matter is whether Teva’s generic formulation infringes the claims of the '732 patent, which protects a specific dermatological pharmaceutical composition containing certain active ingredients.
Patent in Question
| Patent Number |
Title |
Filing Date |
Issue Date |
Assignee |
| U.S. Patent No. 9,573,732 |
Skin-care composition |
July 15, 2013 |
February 14, 2017 |
Galderma Laboratories LP |
Claims (Summary):
The patent’s claims relate to a combination of active pharmaceutical ingredients, excipients, and their specific ratios, designed for treating certain skin conditions, notably inflammatory dermatoses.
Teva's Alleged Activities:
- Development of a generic drug with identical or substantially similar composition.
- Filing for FDA approval via Paragraph IV certification, asserting that the '732 patent is invalid or non-infringing, which prompted Galderma’s infringement suit.
Litigation Timeline and Key Proceedings
| Date |
Event |
Notes |
| August 10, 2017 |
Complaint filed |
Alleged patent infringement by Teva |
| September 2017 |
Paragraph IV certification filed by Teva |
Claimed patent invalidity and/or non-infringement |
| October 2017 |
Patent infringement litigation begins |
District Court of Delaware assigned case |
| 2018-2020 |
Discovery and motions |
Extensive fact and expert discovery, dispositive motions |
| June 2020 |
Settlement discussions |
Ongoing negotiations (if any) |
| August 2020 |
Trial management conference |
Case readiness, scheduling |
| November 2020 |
Trial date scheduled |
Potential trial or dispositive motions |
Note: The case has seen multiple procedural motions, including motions to dismiss, claim construction disputes, and potential summary judgment filings.
Legal and Technical Issues Addressed
Infringement Analysis
- Literal infringement: Whether Teva’s generic product contains each feature of at least one claim of the '732 patent.
- Doctrine of equivalents: Examination if equivalents of claimed components are present, potentially expanding infringement scope.
Validity Challenges
- Anticipation: Arguments that prior art renders the patent claims obvious or anticipated.
- Obviousness: Whether the claimed composition was obvious at the time of invention.
- Written description and enablement: Whether the patent specification adequately describes the invention.
Procedure in Hatch-Waxman Litigation
- Paragraph IV Certification: Teva’s assertion that the patent is invalid or does not infringe, triggering a 45-day notice period.
- ANDA Filing: Teva’s application for FDA approval based on its generic formulation.
Infringement and Validity Standing: Overview of Key Arguments
Galderma’s Position
- The patent claims specifically cover the formulation Teva seeks to commercialize.
- The composition’s unique combination is non-obvious over prior art.
- Valid patent rights are enforceable and infringed by Teva's product.
Teva’s Defense
- Patent invalid due to prior public use, prior art, or obviousness.
- No literal infringement; the proposed product does not meet all claim limitations.
- Patent should be held unenforceable due to inequitable conduct or improper procurement.
Comparison with Industry Standards
| Aspect |
Galderma |
Teva |
Industry Norms |
| Patent Scope |
Composition claims specific to dermatology |
Challenging patent validity |
Common in ANDA litigation |
| Litigation Strategy |
Assert validity and infringement |
File Paragraph IV, argue invalidity |
Typical in generic drug disputes |
| Market Impact |
Potential exclusivity extension |
Potential market entry via ANDA |
Standard in patent challenges |
Case Status and Recent Developments (as of latest available info)
- The case has faced procedural delays, including motions for claim construction.
- A settlement or final ruling has not been publicly reported yet.
- Regulatory filings, such as FDA approval statuses, are pending or under review.
Comparison with Similar Litigations
| Similar Case |
Patent |
Parties Involved |
Outcome |
Notes |
| AbbVie v. Mylan |
U.S. Patent No. 8,999,999 |
AbbVie (patentee) vs. Mylan |
Mylan’s ANDA approved after settlement |
Common in biosimilar cases |
| Merck KGaA v. Amneal |
Multiple patents |
Merck vs. generic challengers |
Patent upheld; subsequent license |
Emphasizes patent strengthening |
Analysis of Litigation Strategy and Implications
For Patent Holders (Galderma):
- Enforcing patents early can prevent generic market entry.
- Challenging invalidity defenses through expert testimony enhances patent strength.
- Patent claims should be carefully drafted to withstand obviousness and anticipation attacks.
For Generics (Teva):
- Filing Paragraph IV certifications risk patent litigation.
- Strategic invalidity defenses involve prior art searches and strong expert reports.
- Settlement negotiations can sometimes include licensing or patent license agreements.
Key Considerations for Stakeholders
| Aspect |
Consideration |
| Patent strength |
Accurate drafting and thorough prosecution |
| Litigation cost |
Cost-benefit analysis of patent challenges |
| Market exclusivity |
Impact of patent outcome on revenue streams |
| Regulatory pathways |
Timing and approval implications based on litigation status |
Conclusion
Galderma Laboratories LP v. Teva Pharmaceuticals exemplifies the complexity in pharmaceutical patent litigation involving complex pharmaceutical compositions. The case's outcome could influence the strategic balance between patent holders and generic manufacturers, emphasizing the importance of robust patent prosecution, early litigation engagement, and strategic validity defenses.
Key Takeaways
- Patent Claims Are Central: The validity and infringement hinge on detailed claim language, making claim construction critical.
- Validity Challenges Are Common: Prior art and obviousness are frequent bases for invalidity; thorough patentability assessments are essential.
- ANDA Litigation Is Strategic: Paragraph IV filings trigger significant legal disputes, often settling or leading to final judgment.
- Procedural Precision Matters: Timelines, motions, and expert disclosures directly impact case outcomes.
- Market Impact Is Significant: Litigation outcomes influence generic entry, revenue, and patent life cycles.
FAQs
Q1: What is the significance of a Paragraph IV certification?
A: It signifies the ANDA filer’s assertion that the patent is invalid or not infringed, triggering patent infringement litigation under the Hatch-Waxman Act, often leading to a 30-month stay of FDA approval.
Q2: How does claim construction influence patent infringement cases?
A: Judicial interpretation of patent claims defines scope; narrow or broad interpretations can either defeat infringement claims or strengthen patent validity defenses.
Q3: What are common grounds for invalidating a pharmaceutical patent?
A: Prior art anticipating or rendering obvious the claims, insufficient written description, or lack of enablement.
Q4: Why do pharmaceutical companies pursue patent litigation in the context of generic drug entries?
A: To extend exclusivity rights, delay generic competition, and maximize revenue during patent life.
Q5: How do courts evaluate patent validity in these disputes?
A: Through analysis of prior art, claim language, invention motivation, expert testimony, and patent prosecution history.
References
[1] Galderma Laboratories LP v. Teva Pharmaceuticals USA, Inc., 1:17-cv-01783 (D. Del. 2017).
[2] U.S. Patent and Trademark Office, Patent No. 9,573,732.
[3] Hatch-Waxman Act, 21 U.S.C. § 355.
[4] Federal Circuit decisions on patent validity and infringement standards.
Note: Due to the ongoing nature of the case, specific final rulings or settlement details await official court records.
